ContractStudy Agreement • August 18th, 2022
Contract Type FiledAugust 18th, 2022Clinical Study AgreementThis Clinical Study Agreement (“Agreement”) betweenIQVIA RDS Czech Republic, s.r.o., having a place of business at Pernerova 691/42, 186 00 Praha 8 - Karlín, Czech Republic, Identification number: 247 68 651, Tax identification number: CZ247 68 651, represented by Ing. Eva Falbrová, Managing Director (“IQVIA”); Caelum Biosciences, Inc., having a place of business at 1200 Florence-Columbus Road, Bordentown NJ 08505-4200, USA, Tax identification number: 57640788100, represented by Doug Schantz, Vice President, Clinical Operations (“Caelum or “Sponsor”); , having a work address at Všeobecná fakultní nemocnice v Praze, U Nemocnice 499/2, 128 08 Praha 2, Česká republika (“Investigator”) and Všeobecná fakultní nemocnice v Praze, having a place of business at U Nemocnice 499/2, 128 08 Praha 2, Czech Republic, Identification number: 00064165, Tax identification number: CZ00064165, represented by(“Institution”), will become effective on the date of its publication in the